TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impella CP With VA ECMO for Cardiogenic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiogenic shock: Including refractory to conventional therapy, including systolic blood pressure \< 90mm Hg, Cardiac Index \< 1.8 or a cardiac index \< 2.0 on moderate to high doses of inotropes and vasopressors for greater than 30 mins, or systemic signs of tissue hypoxia.~* Post-acute myocardial infarction cardiogenic shock: excluding mechanical complications requiring surgical intervention after extracorpeal membrane oxygenator (ECMO) such as post-ischaemic ventricular septal defect (VSD).~* Drug overdose-induced cardiogenic shock.~* Early graft failure: post orthotropic heart transplantation cardiogenic shock, excluding immediate intra-operative failure.~* Acute on chronic cardiomyopathy with progressive shock and decompensation unresponsive to medical therapies.~Exclusion Criteria:~* Recent Significant Pulmonary Embolus~* Moderate to severe aortic valve insufficiency (AI)~* Ongoing significant sepsis~* Severe pulmonary hypertension \& shock~* Hypothermia~* Post-cardiotomy cardiogenic shock~* Continuous cardiopulmonary resuscitation (CPR) \>20-30 minutes, except if neurological status is satisfactory~* Transfer from outside hospital on VA ECMO or with history of CPR~* Listed for cardiopulmonary transplantation or being evaluated for cardiopulmonary transplantation or permanent mechanical circulatory support~* Known or suspected chronic heart failure with echocardiogram documenting left ventricular diastolic diameter \>6.5cm~* Known or suspected chronic heart failure with echocardiogram documenting left ventricular ejection fraction \< 25%~* Mechanical aortic valve replacement~* Presence of left ventricular thrombus~* Pre-existing Impella 2.5, CP, 3.5 or 5.0~* Cardiogenic shock due to primary respiratory failure~* Mechanical complications requiring surgical intervention after ECMO such as post-ischaemic VSD.~* Severe liver failure~* Active malignancy~* Acute aortic dissection~* Intracranial hemorrhage~* Neurological injury including recent cerebrovascular accident or suspected severe neurologic injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): VA-ECMO alone per standard clinical protocol.
- Experimental (Type: EXPERIMENTAL): VA-ECMO with early institution of Impella CP LV venting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Age ≥18~* Willing to exercise five days per week for four weeks, performing each component of the AF PFT at least once per week~* Willing to adhere to a prescribed supplementation regimen, including spaced dosing two times per day~* Able to meet all study follow-up and testing requirements as outlined in section 6.4 of this protocol~Exclusion Criteria:~* History of:~* Chronic kidney dysfunction~* Liver failure~* Rhabdomyolysis~* Compartment syndrome~* Current~* Pregnancy~* Musculoskeletal injury~* Fitness exemption from any component of the AF PFT (e.g. AF 469, profile)~* Kidney injury~* Diabetes~* Hypertension, requiring medication~* Allergy to rice~* Admission to the hospital within the past 30 days~* Creatine supplementation within the past 90 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 30g white rice flour
- Low dose (Type: EXPERIMENTAL): 5g/day Creatine Monohydrate (25g white rice flour) for 28 days
- Loading dose (Type: EXPERIMENTAL): Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
- High dose (Type: EXPERIMENTAL): High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Cohort Study of Hyperpolarized 3He MRI in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent was obtained and documented (after the investigator has given oral and written information about the study to the subject).~* The subject was conscious, co-operative, and agreed to return for the scheduled visits and tests and any visits required to obtain additional safety information.~* The subject's medical history, physical examination (including vital signs, pulse oximetry, PFT's, and 12-lead electrocardiogram \[ECG\]), and clinical laboratory tests (hematology, serum chemistry) obtained at the screening visit were within acceptable limits for entry into the study, as judged by the investigator.~Exclusion Criteria:~* Subject is \<40 or \>70 years old~* Subject known to be pregnant~* Subject with a baseline oxygen requirement \> 2 l/min via nasal cannula~* Any known contraindication to MRI examination~* Inability to provide informed consent~* A language, communication, cognitive or behavioral impairment that might interfere with fully informed consent~* Active drug or alcohol dependence~* Homelessness or other unstable living situation~* Active drug or alcohol dependence~* Significant co-morbidities such as heart disease, kidney disease, liver disease, hematologic or neurological disease that require continuing treatment.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Healthy non-smokers (Type: None): Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
- Asymptomatic smokers (Type: None): Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
- COPD subjects (Type: None): Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of dementia of the Alzheimer's type~Exclusion Criteria:~* History of seizure disorder~* Clinically significant electrocardiogram (ECG)~* Clinical or radiological evidence of stroke, vascular dementia or dementia due to substance abuse, or head trauma

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for \> 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy)~* hormone receptor positive (ER and/or PgR) disease as determined locally~* WHO performance status 0-2~* life expectancy of ≥ 3 months~* the presence of at least one measurable or evaluable (non-measurable) lesion~* informed consent prior to any study procedures~Exclusion Criteria:~* life threatening metastatic visceral disease~* brain or leptomeningeal metastases~* prior exposure to fulvestrant~* history of bleeding diathesis or need for long term anti-coagulation

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT Guided FES Therapy (Type: EXPERIMENTAL): All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* self-identify as African American or Black~* speak English~* present to medical and psychiatric emergency rooms at Grady Health System following a suicide attempt~* moderate level of intent associated with the attempt (SSI \>= 8 required)~* Mini Mental State Exam (MMSE) score \> 22~Exclusion Criteria:~* significant cognitive impairments (MMSE \< 22)~* active psychosis (diagnosed based on Psychotic Screen (PS))~* imminently life-threatening medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Compassion meditation (CM) (Type: EXPERIMENTAL): The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
- Support group (SG) (Type: ACTIVE_COMPARATOR): SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical Diagnosis of a flat keloid.~2. Age 18 to 50~3. A signed informed consent document (ICD)~4. Able and willing to receive bevacizumab~Women of child-bearing potential must have a negative pregnancy test during screening. The effects of bevacizumab on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~Exclusion Criteria:~1. Pedunculated Keloid~2. Diastolic Blood pressure of 90 mm Hg or above~3. History of any degree of Hypertension, even medically controlled hypertension~4. History of any form of cardiovascular disease or stroke~5. History of any form of thromboembolic event~6. History of renal dysfunction or proteinuria~7. History of recent (past 12 month) or planned (next 3 months) major surgery,~8. Men and women who plan to have children within 6 months of their last treatment~9. Psychological Illness that may result in non compliance with treatment~10. Pregnancy and Breast Feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- bevacizumab for all patients (Type: EXPERIMENTAL): This is a single arm trial. All patients receive treatment with bevacizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of DMD based on clinical phenotype with increased serum creatine kinase~2. Documented mutation in the Dystrophin gene associated with DMD that is amenable to exon 51 skipping~3. Ambulatory male, able to walk independently for at least 10 meters in 10 seconds or less at the time of Screening visit (performed as part of the NSAA)~4. Stable pulmonary and cardiac function, as measured by:~   1. Reproducible percent predicted forced vital capacity (FVC) ≥50%~  2. Left ventricular ejection fraction (LVEF) \>55% in patients \<10 years of age and \>45% in patients ≥10 years of age, as measured (and documented) by echocardiogram~5. Currently on a stable corticosteroid therapy regimen, defined as initiation of systemic corticosteroid therapy occurred ≥6 months prior to Screening, and no changes in dosing ≤3 months prior to Screening visit~Exclusion Criteria:~1. Cardiac insufficiency:~   1. Severe cardiomyopathy that, in the opinion of the Investigator, prohibits participation in this study; however, cardiomyopathy that is managed by angiotensin-converting-enzyme (ACE) inhibitors or beta blockers is acceptable provided the patient meets the LVEF inclusion criterion~  2. Any other evidence of clinically significant structural or functional heart abnormality~  3. A cardiac troponin I value \> 0.2 ng/mL~2. Need for daytime mechanical or non-invasive ventilation OR anticipated need for daytime mechanical or non-invasive ventilation within the next year, in the opinion of the Investigator. Nighttime non-invasive ventilation is permitted~3. Received prior treatment with drisapersen or with an investigational peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)~4. Received prior treatment with gene therapy for DMD~5. Received treatment with ataluren or eteplirsen within the 14 weeks prior to the planned Baseline biopsy collection~6. Received any investigational drug within 3 months or 5 half-lives, whichever is longer, prior to the planned Baseline biopsy collection

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- WVE-210201 (3 mg/kg) (Type: EXPERIMENTAL): Weekly IV administrations of WVE-210210 at 3 mg/kg
- WVE-210201 (4.5 mg/kg) (Type: EXPERIMENTAL): Weekly IV administrations of WVE-210210 at 4.5 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cue Reactivity in Virtual Reality: The Role of Context

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years old~2. Self-report of smoking at least 10 cigarettes per day~3. Expired carbon monoxide (CO) equal to or greater than 10 ppm~4. English speaking and able to read at \> 6th grade level~5. Not interested in quitting smoking in next 30 days~Exclusion Criteria:~1) Self-report history of motion sickness or vertigo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cue reactivity in virtual reality (Type: None): Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major depression~Exclusion Criteria:~* Allergy towards pindolol, venlafaxine or other tablet constituents~* Liver or kidney impairment~* Diabetics~* Age below 18 years~* Severe cardiac disease~* Asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Venlafaxine and pindolol
- B (Type: PLACEBO_COMPARATOR): Venlafaxin and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the study treatment regimen and follow-up, must be obtained and documented according to the local regulatory requirements~* Adult women greater than 18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer~  * Cyclin D1 positive as defined as a total immunohistochemical score of 5 or greater~ * Hormone receptor positive as defined as ≥ 10% positive stained cells~ * HER2-normal (IHC score 0-1 or FISH negative \[in-situ hybridization (ISH) ratio \<= 2.0 status\])~* Tumor size at least 5 mm with planned primary surgery at Mount Sinai~* A negative urine dipstick pregnancy test~Exclusion Criteria:~* Estrogen receptor negative invasive breast carcinoma as defined as less than 10% stained cells~* Prior antiestrogen therapy~* Tumor size less than 5 mm~* Prior diagnosis of thrombosis or known hypercoagulable state~* Known history of bleeding diathesis~* Known liver disease~* Prior treatment with neoadjuvant therapy~* Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema).~* Current severe or uncontrolled systemic disease~* Pregnancy or lactation period. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures (barrier methods, intrauterine contraceptive devices) during study treatment.~* Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years prior to randomization, except curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): 750 mg injection in 3 divided doses
- Tamoxifen (Type: ACTIVE_COMPARATOR): 20mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Shoulder pain for at least two weeks.~* Partial thickness articular sided rotator cuff tear diagnosed by MRI and musculoskeletal ultrasound.~Exclusion Criteria:~* Prior surgery to the injured shoulder~* Full thickness rotator cuff tear~* Pregnancy~* Cancer~* Current treatment with anticoagulation medication~* Steroid injection in the past 6 months in the injured shoulder~* Prior PRP treatment to the injured shoulder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- platelet-rich plasma protein (PRP) (Type: EXPERIMENTAL): Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
- Corticosteroid (Type: ACTIVE_COMPARATOR): Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues